Search Results

An updated Peterson-KFF Health System Tracker analysis shows the United States experienced a second year of decline in life expectancy in 2021 while other comparably large, wealthy countries saw a rebound in life expectancy since the onset of the COVID-19 pandemic in 2019.

This fact sheet identifies key U.S. government global health positions and officials.

This tracker provides data on global COVID-19 cases and deaths by country, region, and income-level. Additionally, the tracker reports current closure, economic, and health system policy responses to the COVID-19 pandemic globally. This tracker will be updated as new data are available.

This tracker will be updated regularly to provide data on U.S. COVID-19 vaccine donation deliveries globally.

This page tracks recent state actions to extend Medicaid postpartum coverage, including approved and pending 1115 waivers, legislation that will require the state to seek federal approval through a SPA or 1115 waiver, submitted and approved SPAs, and coverage financed solely with state funds.

This brief describes 10 key points about the unwinding of the Medicaid continuous enrollment requirement, highlighting data and analyses that can inform the unwinding process as well as guidance issued by the Centers for Medicare and Medicaid Services (CMS) to help states prepare for the end of the PHE.

This brief describes current law related to coverage and payment for dental services under Medicare and the rationale for changes to current policy, explains changes to dental payment and coverage included in the final rule, and discusses the impact on Medicare and beneficiaries. This rule modestly expands the types of dental services that are covered under Medicare, but it does not represent a broad expansion of Medicare coverage of dental services and will not substantially increase Medicare spending or covered dental services for a large number of Medicare beneficiaries.

If the federal government runs out of money to purchase COVID-19 vaccines, the per-dose price likely would skyrocket and could increase spending on vaccines by billions of dollars a year, a new KFF analysis finds. To date, the federal government has spent more than $30 billion on COVID-19 vaccines to…

This analysis illustrates the potential total cost of Pfizer and Moderna COVID-19 vaccines, based on their publicly-announced expected prices, once they enter the U.S. commercial market. It compares the average price paid by the federal government for the COVID-19 bivalent boosters to the estimated average commercial prices across different scenarios.